(To Prospectus Dated July 11, 2023)
![[MISSING IMAGE: lg_trawspharma-4clr.jpg]](https://www.sec.gov/Archives/edgar/data/0001130598/000110465925022196/lg_trawspharma-4clr.jpg)
| | |
Page
|
| |||
| | | | S-1 | | | |
| | | | S-2 | | | |
| | | | S-3 | | | |
| | | | S-8 | | | |
| | | | S-9 | | | |
| | | | S-13 | | | |
| | | | S-14 | | | |
| | | | S-15 | | | |
| | | | S-17 | | | |
| | | | S-19 | | | |
| | | | S-19 | | | |
| | | | S-20 | | | |
| | | | S-21 | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 5 | | | |
| | | | 5 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 7 | | | |
| | | | 9 | | | |
| | | | 12 | | | |
| | | | 12 | | | |
| | | | 13 | | | |
| | | | 14 | | | |
| | | | 14 | | |
|
Assumed public offering price per share
|
| | | | | | | | | $ | 2.72 | | |
|
Historical net tangible book value per share as of September 30, 2024
|
| | | $ | (0.339) | | | | | | | | |
|
Increase in historical net tangible book value per share attributable to the pro forma adjustments described above
|
| | | $ | 0.032 | | | | | | | | |
|
Pro forma net tangible book value per share as of September 30, 2024
|
| | | $ | (0.307) | | | | | | | | |
|
Increase in pro forma net tangible book value per share attributable to new investors
|
| | | $ | 0.482 | | | | | | | | |
|
Pro forma as adjusted net tangible book value per share after this offering
|
| | | | | | | | | $ | 0.175 | | |
|
Dilution per share to new investors
|
| | | | | | | | | $ | 2.545 | | |
ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES
Traws Pharma, Inc.
12 Penns Trail
Newtown, PA 18940
(267) 759-3680
![[MISSING IMAGE: lg_onconova-4c.jpg]](https://www.sec.gov/Archives/edgar/data/0001130598/000110465925022196/lg_onconova-4c.jpg)
Common Stock, Preferred Stock,
Debt Securities, Warrants and Units
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 5 | | | |
| | | | 5 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 7 | | | |
| | | | 9 | | | |
| | | | 12 | | | |
| | | | 12 | | | |
| | | | 13 | | | |
| | | | 14 | | | |
| | | | 14 | | |